MK-677

MK-677 (Ibutamoren) is neither a traditional peptide nor a SARM. It is a non-peptide ghrelin mimetic and growth hormone secretagogue that is taken orally. It mimics the action of ghrelin at the GHS-R1a receptor to stimulate growth hormone release. Its oral bioavailability and long half-life (~24 hours) distinguish it from injectable peptide secretagogues.

The standard dosage is 10-25 mg taken once daily, typically before bed to align with the natural GH pulse during sleep. Starting at 10 mg for the first 1-2 weeks helps assess tolerance, particularly regarding appetite stimulation and water retention. Most users settle on 15-25 mg daily for the duration of the cycle.

Yes, increased appetite is one of the most common side effects of MK-677 due to its action on ghrelin receptors. This effect is most pronounced during the first 2-4 weeks and tends to diminish somewhat with continued use. Taking MK-677 before bed rather than in the morning can help mitigate appetite-related issues during the day.

Yes, MK-677 can increase fasting blood glucose and reduce insulin sensitivity, particularly at higher doses or with long-term use. This is a known effect of elevated growth hormone levels. Monitoring fasting glucose is recommended, especially for individuals with pre-existing insulin resistance. Berberine or metformin are sometimes used alongside to manage this effect.

MK-677 cycles typically last 8-16 weeks, though some protocols extend to 6-12 months given its oral convenience. GH and IGF-1 elevations remain sustained without significant desensitization. However, longer cycles require monitoring of blood glucose and insulin sensitivity. A common approach is 3 months on followed by 1 month off.